NASDAQ:CASI
CASI Pharmaceuticals Stock News
$2.80
+0.115 (+4.29%)
At Close: May 03, 2024
OncoSec Announces Appointment of George Chi as Chief Financial Officer
10:59pm, Tuesday, 22'nd Feb 2022 Kwhen FinanceCASI Pharmaceuticals sees Q4 revenue ahead of analysts estimates
01:01pm, Wednesday, 16'th Feb 2022 Seeking Alpha
CASI Pharmaceuticals (CASI) expects EVOMELA revenue of ~$9.12M for Q4 and ~$30M (+100% Y/Y) for FY ended Dec.31,2021 which exceeds the estimated $27M guidance.Analysts consensus…
CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES
12:00pm, Wednesday, 16'th Feb 2022 PR Newswire
ROCKVILLE, Md. and BEIJING, Feb. 16, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced preliminary and unaudited revenues for the…
CASI announces FDAs Orphan Drug Designation for follicular lymphoma candidate
01:11pm, Thursday, 20'th Jan 2022 Seeking Alpha
CASI Pharmaceuticals (CASI) announced that the FDA had awarded its partner BioInvent International, the Orphan Drug Designation (ODD) for an investigational therapy targeted at
CASI''s partner Juventas'' CNCT19 for blood cancer gets FDA orphan drug status
02:54pm, Tuesday, 18'th Jan 2022 Seeking Alpha
CASI Pharmaceuticals <> said the U.S. Food and Drug Administration ((FDA)) has granted orphan drug designation to its partner Juventas Cell Therapy''s medicine CNCT19 to
CASI Pharmaceuticals Inc Shares Approach 52-Week Low - Market Mover
10:09pm, Saturday, 15'th Jan 2022 Kwhen Finance
CASI Pharmaceuticals Inc (CASI) shares closed today at 0.5% above its 52 week low of $0.72, giving the company a market cap of $101M. The stock is currently down 9.7% year-to-date, down 78.3% over the past 12 months, and down 42.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 184.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.0% lower than its 5-day moving average, 10.8% lower than its 20-day moving average, and 29.9% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -14.5% The company's stock price performance over the past 12 months lags the peer average by 154.6%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Hilly Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Gran Tierra Energy Inc. (AMEX:GTE)
04:40am, Friday, 24'th Dec 2021 Stock Equity
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) with the stream of 2.18% also noticed, India Gran Tierra Energy Inc. (AMEX:GTE) encountered a rapid change of -0.07% in the last hour of Thursdays trading The post Hilly Stock: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Gran Tierra Energy Inc. (AMEX:GTE) appeared first on Stocks Equity .
CASI Pharmaceuticals jumps 12% on repurchase of stock upto $10M
12:55pm, Friday, 17'th Dec 2021 Seeking AlphaThe Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
12:54pm, Friday, 17'th Dec 2021 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral COVID-19 Antiviral Treatmen
CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM
12:00pm, Friday, 17'th Dec 2021 PR Newswire
ROCKVILLE, Md. and BEIJING, Dec. 17, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), (the "Company" or "CASI"), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that its board of
Head to Head Comparison: Valneva (NASDAQ:VALN) versus CASI Pharmaceuticals (NASDAQ:CASI)
09:18am, Monday, 13'th Dec 2021 ETF Daily News
CASI Pharmaceuticals (NASDAQ:CASI) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk. Analyst Recommendations This is a summary of recent ratings and price targets for CASI Pharmaceuticals and Valneva, [] The post Head to Head Comparison: Valneva (NASDAQ:VALN) versus CASI Pharmaceuticals (NASDAQ:CASI) appeared first on ETF Daily News .
Top Stock Picks for the Day: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Senseonics Holdings, Inc. (AMEX:SENS)
12:34am, Monday, 13'th Dec 2021 Stock Equity
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) with the stream of -2.09% also noticed, India Senseonics Holdings, Inc. (AMEX:SENS) encountered a rapid change of -3.45% in the last hour of Fridays trading session. The post Top Stock Picks for the Day: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Senseonics Holdings, Inc. (AMEX:SENS) appeared first on Stocks Equity .
Things To Consider When Buying CASI Pharmaceuticals Inc. (NASDAQ:CASI) Shares
04:00pm, Friday, 10'th Dec 2021 Stocks Register
CASI Pharmaceuticals Inc. (NASDAQ:CASI) price on Thursday, December 09, fall -2.24% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.86. A look at the stocks price movement, the close in the last trading session was $0.88, moving within a range at $0.8581 and $0.9125. The beta value Things To Consider When Buying CASI Pharmaceuticals Inc. (NASDAQ:CASI) Shares Read More »
BioInvent International: BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
12:20pm, Friday, 10'th Dec 2021 FinanzNachrichten
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class…
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
11:07am, Monday, 06'th Dec 2021 Benzinga
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r